Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Enrolled patients followed a diagnostic-therapeutic pathway, consisting of the following steps:
* t0: MR with DTI-ALPS study;
* t1 (within 7 days from T0): clinical and neurosurgical assessment with NPH-specific rating scales (detailed below) before and after a lumbar TT, including measurements of opening pressure, drainage of 40-50 mL of CSF and collection of samples for neurodegenerative biomarkers (β-Amyloid 40, 42 total and P-Tau) quantification. An MR with DTI-ALPS study within 6 hours from TT;
* t2 (within 3 months from T1): patients with a positive TT response (included responders, IR group) underwent VPS surgery, with CSF samples collected for the same neurodegenerative biomarkers (β-Amyloid 40, 42 total and P-Tau);
* t3 (three months after surgery, IR group only): clinical and neurosurgical evaluation using NPH-specific rating scales to classify patients as improved, unchanged, or worsened compared to their preoperative condition; MR with DTI-ALPS study.
Age
50–any
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Suspected NPH patients according to the following:
clinical and radiological diagnosis of probable NPH according to existing guidelines
age of over 50 years
You may not be if
inability to undergo MR
diagnosis of any other neurological pathology, particularly neurodegenerative or neuroinflammatory
previous neurosurgical interventions on the brain of any type.